Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon for Children With Congenital Hyperinsulinism
NCT03777176Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of dasiglucagon in congenital hyperinsulinism (HI), sponsored by Zealand Pharma. Started Feb 2019; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT03777176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777176.